The Misuse of Drugs Act 1971 (Amendment) Order 2022
At the Court at Windsor Castle, the 16th day of March 2022
Present,
The Queen’s Most Excellent Majesty in Council
Accordingly, Her Majesty, in exercise of the powers conferred on Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:
Citation, commencement and extent1.
(1)
This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2022 and comes into force twenty-eight days after the day on which it is made.
(2)
This Order extends to England and Wales, Scotland and Northern Ireland.
Amendments to the Misuse of Drugs Act 19712.
(1)
The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.
(2)
(a)
after “N-Benzyl-ethylphenidate.” insert “1,4-Butanediol.”
;
(b)
after “Ethylphenidate.” insert “Gamma-butyrolactone.”
;
(c)
after “Glutethimide.” insert “4-Hydroxy-n-butyric acid.”
.
(3)
(a)
omit “Gamma-butyrolactone”;
(b)
omit “4-Hydroxy-n-butyric acid”.
(4)
This Order reclassifies 1,4-Butanediol (1,4-BD), Gamma-butyrolactone (GBL) and 4-Hydroxy-n-butyric acid (GHB) from Class C to Class B drugs for the purposes of control under the Misuse of Drugs Act 1971 (c. 38).
A full impact assessment of the effect that this instrument will have on the costs of business, the voluntary sector and the public sector is submitted alongside the Explanatory Memorandum which is available alongside the instrument at www.legislation.gov.uk. Copies may be obtained from the Home Office at 2 Marsham Street, London, SW1P 4DF.